Table 4.
Patients (N) | Presence of resistant isolates - number (%) | |||||
β-lactams | AMN | CHR | QNL | RF | TE | |
Periodontally healthy subjects (N=50) | 5 (10.0) | 0 (0.0) | 2 (4.0) | 3 (6.0) | 0 (0.0) | 11 (22.0) |
Patients with gingivitis (N= 89) | 29 (32.6) | 21 (23.6) | 10 (11.2) | 9 (10.1) | 2 (2.2) | 20 (22.5) |
Patients with periodontitis (N= 70) | 55 (78.6) | 31 (44.3) | 9 (12.9) | 12 (17.1) | 1 (1.4) | 28 (40.0) |
Edentulous patients (N=41) | 34 (82.9) | 23 (56.1) | 28 (68.3) | 23 (56.1) | 6 (14.6) | 27 (65.9) |
AMN, aminoglycosides; CHR, chloramphenicol; QNL, quinolones; RF, rifampin; TE, tetracycline.